Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress

• Update on RSV F Vaccine Phase 3 Prepare(TM) trial for infants via maternal immunization
• Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose flu vaccine

GAITHERSBURG, Md., April 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced it will present on its two lead vaccine programs at the World Vaccine Congress, April 2-5 in Washington, D.C. These presentations include details from the Phase 3 Prepare(TM) trial of its RSV F vaccine for infants via maternal immunization, as well as positive results from the Phase 1/2 trial of NanoFlu recombinant influenza vaccine, including its proprietary Matrix-M(TM) adjuvant, in older adults.

"We look forward to sharing this meaningful information and data from our key vaccine clinical trials with the international infectious disease community next week at the World Vaccine Congress," said Stanley C. Erck, President and CEO, Novavax, Inc. "Our RSV F and NanoFlu vaccines both have strong potential to have significant impact on global public health. We look forward to continuing the advancement of the NanoFlu program and to completing the RSV Prepare trial and preparing the BLA for this program." 

Details for the two presentations are as follows:

Title: "The RSV F nanoparticle vaccine for infants via maternal immunization in Phase 3: rationale and update"
Date and Time: Wednesday, April 4, 11:40 a.m. 
Presenter: Gregory M. Glenn, M.D., President of Research and Development, Novavax

Title: "Novavax NanoFlu vaccine induced improved immune responses against homologous and drifted A/H3N2 viruses in older adults compared to egg-based, high-dose, influenza vaccine"
Date and Time: Wednesday, April 4, 3:55 p.m.
Presenter: Vivek Shinde, M.D., Director of Clinical Development, Novavax

About RSV

RSV is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively.¹ In the US, RSV is the leading cause of hospitalization of infants.² Despite the induction of post-infection immunity, repeat infection and lifelong susceptibility to RSV is common.³ Currently, there is no approved RSV vaccine available.